Stockreport

Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

Adamas Pharmaceuticals, Inc.  (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
PDF - INROADS study achieved its primary endpoint (proportion of responders with at least a 20% improvement from baseline to Week 12) - - Dose-response observed for both ef [Read more]